Anti-Japanese Encephalitis Virus (Clone: JEV-75)
| Code | Size | Price |
|---|
| LEI-LT563-250ug | 250 ug | £231.00 |
Quantity:
| LEI-LT563-1.0mg | 1.0 mg | £410.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Virus
Antibody Isotype: Human IgG1λ
Antibody Clonality: Monoclonal
Antibody Clone: JEV-75
Regulatory Status: RUO
Target Species:
- Japanese Encephalitis
- Virus
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Neutralisation
Shipping:
Blue Ice
Storage:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage aseptically aliquot in working volumes without diluting and store at ? -70°C. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
A panel of human mAbs against JEV, including JEV-75, was generated from donors immunized with a GIII vaccine strain (JEV-SA14-14-2)2.
Long Description:
Japanese Encephalitis Virus (JEV) is a mosquito-borne, enveloped, positive-stranded RNA virus in the Flavivirus genus endemic to Asia and parts of the western Pacific1. Symptomatic JEV infection is most common in children in areas of endemicity or travellers to those regions. Severe symptoms occur in ~1% of cases, with a case-fatality ratio of 20?30%. Survivors often have serious neurologic, cognitive, or psychiatric sequelae. Five JEV genotypes have been identified and existing vaccines are derived from historically predominant GIII strains2.
Purity:
?95% monomer by analytical SEC
Target:
Japanese Encephalitis Virus
References
1. Hills SL, Lindsey NP, Fischer M. Chapter 4: Travel-Related Infectious Diseases, Japanese Encephalitis. In: Brunette GW, Nemhauser JB, eds. 2020 CDC Yellow Book. CDC; National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Global Migration and Quarantine (DGMQ), Link Text
2. Fernandez E, Kose N, Edeling MA, et al. mBio. 9(1):e00008-18. 2018.
Related Products
| Product Name | Product Code | Supplier | Anti-Japanese Encephalitis Virus (Clone: JEV-69) | LEI-LT564 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|